A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Sponsor

BeiGene (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04746924

Collaborator

(none)

605

Enrollment

224

Locations

Arms

46.8

Anticipated Duration (Months)

2.7

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to compare progression-free survival (PFS) between Arm A (ociperlimab in combination with tislelizumab) and Arm B (pembrolizumab in combination with placebo) as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and to compare overall survival (OS) between Arm A and Arm B.

Condition or Disease	Intervention/Treatment	Phase
Non-small Cell Lung Cancer NSCLC	Drug: Tislelizumab Drug: Ociperlimab Drug: Pembrolizumab Drug: Placebo	Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

605 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Care Provider, Investigator)

Primary Purpose:

Treatment

Official Title:

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Actual Study Start Date :

Jun 8, 2021

Anticipated Primary Completion Date :

Jan 1, 2025

Anticipated Study Completion Date :

May 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm A: Tislelizumab plus Ociperlimab Participants will receive ociperlimab 900 mg intravenously followed by tislelizumab 200 milligrams (mg) intravenously once every 3 weeks.	Drug: Tislelizumab Tislelizumab is a monoclonal antibody formulated for intravenous injection. Other Names: BGB-A317 Drug: Ociperlimab Ociperlimab is a monoclonal antibody formulated for intravenous injection. Other Names: BGB-A1217
Active Comparator: Arm B: Pembrolizumab plus Placebo Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.	Drug: Pembrolizumab Pembrolizumab is a monoclonal antibody formulated for intravenous injection. Other Names: KEYTRUDA Drug: Placebo Placebo infusions will consist of a sterile, normal saline solution.
Placebo Comparator: Arm C: Tislelizumab plus Placebo Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.	Drug: Tislelizumab Tislelizumab is a monoclonal antibody formulated for intravenous injection. Other Names: BGB-A317 Drug: Placebo Placebo infusions will consist of a sterile, normal saline solution.

Arm

Intervention/Treatment

Experimental: Arm A: Tislelizumab plus Ociperlimab

Participants will receive ociperlimab 900 mg intravenously followed by tislelizumab 200 milligrams (mg) intravenously once every 3 weeks.

Drug: Tislelizumab

Tislelizumab is a monoclonal antibody formulated for intravenous injection.

Other Names:

BGB-A317

Drug: Ociperlimab

Ociperlimab is a monoclonal antibody formulated for intravenous injection.

Other Names:

BGB-A1217

Active Comparator: Arm B: Pembrolizumab plus Placebo

Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.

Drug: Pembrolizumab

Pembrolizumab is a monoclonal antibody formulated for intravenous injection.

Other Names:

KEYTRUDA

Drug: Placebo

Placebo infusions will consist of a sterile, normal saline solution.

Placebo Comparator: Arm C: Tislelizumab plus Placebo

Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.

Drug: Tislelizumab

Tislelizumab is a monoclonal antibody formulated for intravenous injection.

Other Names:

BGB-A317

Drug: Placebo

Placebo infusions will consist of a sterile, normal saline solution.

Outcome Measures

Primary Outcome Measures

Progression-free Survival (PFS) As Assessed By Investigators [Up to approximately 40 months]
PFS will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first.
Overall Survival (OS) As Assessed By Investigators [Up to approximately 40 months]
OS will be defined as the time from the date of randomization to the date of death due to any cause.

Secondary Outcome Measures

PFS As Assessed By A Blinded Independent Review Committee [Up to approximately 40 months]
PFS will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first.
Overall Response Rate (ORR) As Assessed By Investigators [Up to approximately 40 months]
ORR will be defined as the proportion of participants with a documented, confirmed complete response or partial response per RECIST v1.1.
Duration Of Response (DOR) As Assessed By Investigators [Up to approximately 40 months]
DOR will be defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first.
Health-related Quality Of Life (HRQoL): European Organization For Research And Treatment Of Cancer Quality Of Life Questionnaire Core 30 (EORTC QLQ-C30) [Within 7 days after last dose]
HRQoL will be assessed via patient-reported outcomes (PRO) using the EORTC QLQ-C30. The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome
HRQoL: EORTC Lung Cancer Module Quality Of Life Questionnaire Lung Cancer 13 (QLQ-LC13) [Within 7 days after last dose]
HRQoL will be assessed via PRO using the EORTC QLQ-LC13. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) A score of 1-4 will be administrated for each item in QLQ-LC13. The higher scores will indicate the worse outcomes.
HRQoL: The 5 Level EuroQol 5 Dimension (EQ-5D-5L) Questionnaire [Within 7 days after last dose]
HRQoL will be assessed via PRO using the EQ-5D-5L. EQ-5D-5L - Is the EuroQol 5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Time To Deterioration (TDD) [Within 7 days after last dose]
TDD will be analyzed using the global health status of QLQ-C30 and will be defined as worsening scores for 2 consecutive assessments or 1 assessment followed by death from any cause.
Number Of Participants Experiencing Adverse Events (AEs) [90 days (±14) after last dose]
The incidence and severity of AEs will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0).

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Key Inclusion Criteria:

Histologically or cytologically documented locally advanced or recurrent non-small cell lung cancer (NSCLC) that is not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic-nonsquamous or squamous NSCLC.
No prior systemic treatment for metastatic NSCLC.
Agreement to provide archival tissue or fresh biopsy (if archival tissue is not available).
Tumors with PD-L1 tumor cell ≥ 50% expression.
At least 1 measurable lesion as defined per RECIST v1.1.
ECOG Performance Status ≤ 1.

Key Exclusion Criteria:

Known mutations in the epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, or ROS1.
Prior therapy with an anti-programmed cell death protein (anti-PD)-1, anti-PD-ligand (L)-1, anti-PD-ligand-2, anti-T-cell immunoglobulin and ITIM (anti-TIGIT) domain, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
Active autoimmune diseases or history of autoimmune diseases that may relapse.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	UAB O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham	Birmingham	Alabama	United States	35294
2	Alaska Oncology and Hematology, LLC	Anchorage	Alaska	United States	99508
3	Providence Medical Foundation	Fullerton	California	United States	92835
4	Ocala Oncology, Florida Cancer Affiliates	Ocala	Florida	United States	34474
5	Advent Health Oncology and Hematology	Orlando	Florida	United States	32804
6	Goshen Center for Cancer Care	Goshen	Indiana	United States	46526
7	Baptist Health Lexington	Lexington	Kentucky	United States	40503
8	West Jefferson Medical Center Cancer Center (University Medical Center New Orleans)	Marrero	Louisiana	United States	70072
9	Central Maine Medical Center	Lewiston	Maine	United States	04240
10	HealthPartners Institute - MMCORC (Metro Minnesota Community Oncology Research Consortium)	Saint Paul	Minnesota	United States	55426
11	XCancer / Central Care Cancer Center	Bolivar	Missouri	United States	65613
12	Penn State Health Cancer Institute	Hershey	Pennsylvania	United States	17033
13	West Penn Hospital (Allegheny Health Network)	Pittsburgh	Pennsylvania	United States	15224
14	Virginia Cancer Specialist, PC	Fairfax	Virginia	United States	22031
15	Concord Repatriation General Hospital	Concord	New South Wales	Australia	2139
16	Northern Cancer Institute, Genesis Care	Saint Leonards	New South Wales	Australia	2065
17	Calvary Mater Newcastle, Medical Oncology Trial Unit, Edith Street	Waratah	New South Wales	Australia	2298
18	Pindara Private Hospital	Benowa	Queensland	Australia	4217
19	The Prince Charles Hospital	Chermside	Queensland	Australia	4032
20	Mater Cancer Care Centre	South Brisbane	Queensland	Australia	4101
21	John Flynn Private Hospital	Tugun	Queensland	Australia	4224
22	Lyell McEwin Hospital	Elizabeth Vale	South Australia	Australia	5112
23	Ballarat Health Services	Ballarat	Victoria	Australia	3350
24	Monash Health	Clayton	Victoria	Australia	3168
25	Western Health - Sunshine Hospital	St Albans	Victoria	Australia	3021
26	St John of God, Murdoch Hospital	Murdoch	Western Australia	Australia	6150
27	Anhui Provincial Hospital	Hefei	Anhui	China	230000
28	Beijing Cancer Hospital	Beijing	Beijing	China	100142
29	Beijing Chest Hospital, Capital Medical University	Beijing	Beijing	China	10149
30	Southwest Hospital	Chongqing	Chongqing	China	400038
31	Chongqing Three Gorges Central Hospital	Chongqing	Chongqing	China	404000
32	Fujian Medical University Union Hospital	Fuzhou	Fujian	China	350001
33	Fujian Cancer Hospital	Fuzhou	Fujian	China	350014
34	The First Affiliated Hospital of Xiamen University	Xiamen	Fujian	China	361003
35	Cancer Center of Guangzhou Medical University	Guangzhou	Guangdong	China	510030
36	Cancer Hospital of Shantou University Medical College	Shantou	Guangdong	China	515031
37	Shenzhen People's Hospital	Shenzhen	Guangdong	China	518020
38	Cancer Hospital of Guangxi Zhuang Autonomous Region	Nanning	Guangxi	China	530021
39	The People's Hospital of Guangxi Zhuang Autonomous Region	Nanning	Guangxi	China	530021
40	Affiliated Tumor Hospital of Harbin Medical University	Harbin	Heilongjiang	China	150000
41	The First Affiliated Hospital of Zhengfzhou University	Zhengzhou	Henan	China	400052
42	Henan Cancer Hospital	Zhengzhou	Henan	China	450000
43	Henan Provincial People's Hospital	Zhengzhou	Henan	China	450003
44	Hubei Cancer Hospital	Wuhan	Hubei	China	400037
45	Union Hospital of Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei	China	430023
46	Renmin Hospital of Wuhan University	Wuhan	Hubei	China	430060
47	The Second Xiangya Hospital of Central South University	Changsha	Hunan	China	410011
48	Nanjing First Hospital	Nanjing	Jiangsu	China	210009
49	Nanjing Chest Hospital	Nanjing	Jiangsu	China	210029
50	The First Affiliated Hospital of Soochow University	Suzhou	Jiangsu	China	215006
51	Liaoning Cancer Hospital & Institute	Shenyang	Liaoning	China	110042
52	The Affiliated Hospital of Qingdao University	Qingdao	Shandong	China	266000
53	Weifang People's Hospital	Weifang	Shandong	China	261000
54	Shanghai Chest Hospital	Shanghai	Shanghai	China	200030
55	Shanxi Bethune Hospital	Taiyuan	Shanxi	China	030032
56	Sichuan Cancer Hospital & Institute	Chengdu	Sichuan	China	610041
57	Tianjin Medical University General Hospital	Tianjin	Tianjin	China	300052
58	Tianjin Medical University Cancer Institute & Hospital	Tianjin	Tianjin	China	300060
59	Affiliated Cancer Hospital of Xinjiang Medical University	Ürümqi	Xinjiang	China	830000
60	Sir Run Run Shaw Hospital, Zhejiang University School of Medicine	Hangzhou	Zhejiang	China	310016
61	Zhejiang Cancer Hospital	Hangzhou	Zhejiang	China	310022
62	Ningbo First Hospital	Ningbo	Zhejiang	China	315010
63	Beijing Chao-Yang Hospital	Beijing		China	100020
64	Peking Union Medical College Hospital	Beijing		China	100730
65	Hunan Cancer Hospital	Changsha		China	410013
66	Changzhou No.2 People's Hospital	Changzhou		China	213003
67	West China Hospital, Sichuan University	Chengdu		China	610041
68	Chongqing Cancer Hospital	Chongqing		China	400030
69	Daping Hospital, Third Military Medical University	Chongqing		China	400042
70	The First Affiliated Hospital of Guangzhou Medical University	Guangzhou		China	510120
71	The Second Hospital of Anhui Medical University	Hefei		China	230601
72	The First Affiliated Hospital of Nanchang University	Nanchang		China	330006
73	Affiliated Hospital of North Sichuan Medical College	Nanchong		China	637000
74	Affiliated Zhongshan Hospital of Fudan University	Shanghai		China	200032
75	Shanghai Pulmonary Hospital	Shanghai		China	200433
76	The Second Affiliated Hospital of Soochow University	Suzhou		China	215000
77	Taizhou Hospital of Zhejiang Province	Taizhou		China	317000
78	The First Affiliated Hospital of Xi'an Jiaotong University	Xi'an		China	710061
79	Xuzhou Central Hospital	Xuzhou		China	221000
80	Yantai Yuhuangding Hospital	Yantai		China	264000
81	The Fourth Affiliated Hospital Zhejinaang University School of Medicine	Yiwu		China	322000
82	Institut de Cancérologie de L'Ouest	Angers		France	49055
83	Centre Hospitalier de la Cote Basque - Saint Léon - Service de Pneumologie	Bayonne		France	64109
84	Hospices Civils de Lyon- Hopital Louis Pradel	Bron		France	69500
85	CHI de Creteuil	Créteil		France	94000
86	Hospices Civils de Lyon-Hôpital de la Croix Rousse	Lyon		France	69004
87	Centre Leon Berard	Lyon		France	69373
88	ICM Val Daurelle - Oncologie Médicale	Montpellier		France	34298
89	Centre Hospitalier Emile Muller Ghrmsa	Mulhouse		France	68100
90	Clinique Gentilly	Nancy		France	54100
91	Hopital Cochin	Paris		France	75014
92	Hospices Civils de Lyon- Centre Hospitalier Lyon Sud	Pierre-Bénite		France	69310
93	HIA Begin	Saint-Mandé		France	94160
94	Chu Tours - Hopital Bretonneau - Service Pneumologie 2	Tours		France	37000
95	High Technology Hospital Medcenter LTD	Batumi		Georgia	6000
96	Acad. Fridon Todua medical Center LTD - Research Institute of Clinical Medicine LTD	Tbilisi		Georgia	0112
97	Israel-Georgian Medical Research Clinic Helsicore LTD	Tbilisi		Georgia	0112
98	Multiprofile Clinic Consilium Medula LTD	Tbilisi		Georgia	0186
99	Oncology Research Center LTD	Tbilisi		Georgia	0186
100	Timi - Tbilisi Institute of Medicine LTD	Tbilisi		Georgia	0186
101	Universitaetsklinikum Aachen	Aachen		Germany	52074
102	Helios Klinikum Bad Saarow	Bad Saarow		Germany	15526
103	Charite Universitatsmedizin Berlin	Berlin		Germany	13353
104	Asklepios Fachklinik Munchen-Gauting	Gauting		Germany	82131
105	Lungenclinic Grosshansdorf GMBH	Großhansdorf		Germany	22927
106	Ambulantes Krebszentrum Hamburg	Hamburg		Germany	20251
107	Uniklinikum Giessen Marburg	Heidelberg		Germany	35392
108	Universitatsklinikum Bonn	Kiel		Germany	53127
109	Kliniken Der Stadt Koeln GGMBH	Köln		Germany	51109
110	Onkologische Scwerpunktpraxis Leer - Emden	Leer		Germany	26789
111	Klinikum Ludwigshafen, Medizinische Klinik A	Ludwigshafen		Germany	67063
112	Klinikum Johannes-Gutenberg-Universitaet Mainz	Mainz		Germany	55131
113	Klinikum Der Universitat muenchen - Campus Innenstadt	Muenchen		Germany	80336
114	Muenchen Klinik Bogenhausen	Muenchen		Germany	80336
115	Agaplesion Diakonieklinikum Rotenburg Gemeinnutzige GMBH	Rotenburg		Germany	27356
116	Universitaetsklinikum Ulm, Innere Medizin III	Ulm		Germany	89081
117	Onkologische Schwerpunkt-Praxis-Worms	Worms		Germany	57547
118	Cro Irccs Aviano	Via Franco Gallini	Aviano	Italy	33081
119	Istituto Romagnolo per Studio, dei Tumori "Dino Amadori"	Meldola		Italy	47017
120	Azienda Ospedaliera Papardo	Messina		Italy	98158
121	Ospedale San Raffaele	Milano		Italy	20132
122	Aou San Luigi Gonzaga	Orbassano		Italy	10043
123	Arcispedale S. Maria Nuova - Ausl Reggio Emilia - Oncologia	Reggio Emilia		Italy	42123
124	Azienda Ospedaliera Universitaria Integrata Di Verona	Verona		Italy	37126
125	Nagoya University Hospital	Nagoya	Aichi	Japan	003-0804
126	Kobe City Medical Center General Hospital	Kobe	Hyogo	Japan	650-0047
127	Okayama University Hospital	Okayama-shi	Okayama-ken	Japan	700-8558
128	Cancer Institute Hospital of JFCR	Koto-ku	Tokyo-To	Japan	135-8550
129	Kanagawa Cancer Center	Kanagawa		Japan	241-8515
130	Nagaoka Red Cross Hospital	Niigata		Japan	940-2085
131	The Catholic University of Korea, Bucheon St. Mary's Hospital	Gyeonggi-do	Bucheon-si	Korea, Republic of	14647
132	Kyungpook National University Chilgok Hospital	Daegu	Buk-gu	Korea, Republic of	41404
133	Chungbuk National University Hospital	Cheongju-si	Chungcheongbuk-do	Korea, Republic of	28644
134	Keimyung University Dongsan Hospital	Daegu	Dalseo-gu	Korea, Republic of	42601
135	The Catholic University of Korea Eunpyeong St. Mary's Hospital	Seoul	Eunpyeong-gu	Korea, Republic of	03312
136	Inje University Haeundae Paik Hospital	Busan	Haeundae-gu	Korea, Republic of	48108
137	Meander Medisch Centrum	Amersfoort		Netherlands	3813
138	Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis	Amsterdam		Netherlands	1066
139	Rijnstate	Arnhem		Netherlands	6815
140	Ziekenhuis St Jansdal	Harderwijk		Netherlands	3844
141	Stichting Zuyderland Medisch Centrum	Heerlen		Netherlands	6419
142	Isala Klinieken Zwolle	Zwolle		Netherlands	8025
143	Uniwersytecki Szpital Kliniczny w Białymstoku	Białystok		Poland	15-276
144	Szpitale Pomorskie Spółka z ograniczoną odpowiedzialnością	Gdynia		Poland
145	Przychodnia Med-Polonia Sp. z o.o.	Poznan		Poland	60-693
146	Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi	Łódź		Poland
147	Arkhangelsk Regional Clinical Oncological Dispensary	Arkhangel'sk		Russian Federation	163045
148	State Budgetary Healthcare Institution-Chelyabinsk Regional Clinical Center of Oncology and Nuclear	Chelyabinsk		Russian Federation	454087
149	Regional Budgetary Healthcare Institution "G.E. Ostroverkhov Kursk Oncology Scientific and Clinical"	Kursk		Russian Federation	305035
150	State Budgetary Healthcare Institution-Regional Oncology Dispensary Number 2	Magnitogorsk		Russian Federation	455001
151	"Vitamed" LLC	Moscow		Russian Federation	121309
152	State Budgetary Healthcare Institution "City Clinical Hospital #1"	Nalchik		Russian Federation	360000
153	State Budgetary Healthcare Institution - Nizhny Novgorod Regional Clinical Oncology Dispensary	Nizhny Novgorod		Russian Federation	603081
154	BIH of OMSK Region "Clinical Oncology Dispensary"	Omsk		Russian Federation	644013
155	Private Healthcare Institution - Clinical Hospital Russian Railways - Medicine of the City of St. Petersburg	Saint Petersburg		Russian Federation	195271
156	Private Medical Institution "Evromedservis"	Saint Petersburg		Russian Federation	196603
157	LLC AV-Medical Group	Saint Petersburg		Russian Federation	197082
158	The Smorodintsev Research Institute of Influenze	Saint Petersburg		Russian Federation	197376
159	FSBI "Clinical Research and Practical Center for Specialized Medical Care (Oncology)"	Saint Petersburg		Russian Federation	197758
160	FSBI "National Medical Research Center for Oncology N.A.N.N. Petrov" of the MOH of the RF	Saint Petersburg		Russian Federation	197758
161	State Budgetary Healthcare Institution - Samara Regional Clinical Oncology Dispensary	Samara		Russian Federation	443031
162	Federal State Budgetary Educational Institution of Higher Education "National Research Ogarev Morodov"	Saransk		Russian Federation	430032
163	State Autonomous Healthcare Institution - Republican Clinical Oncological Dispensary of the Republic	Ufa		Russian Federation	450054
164	ICO-H.U.G. Trias I Pujol	Badalona		Spain	08916
165	Hospital Del Mar	Barcelona		Spain	08003
166	Hospital Universitari Quiron Dexeus	Barcelona		Spain	08028
167	Hospital Universitario Vall D'Hebron	Barcelona		Spain	8035
168	Hospital Universitario Donostia	Donostia		Spain	20014
169	Hospital General Universitario de Elche	Elche		Spain	03203
170	ICO Girona	Girona		Spain	17007
171	Hospital Universitario Insularde Gran Canaria	Las Palmas		Spain	35016
172	Hospital Universitario Lucus Augusti	Lugo		Spain	27003
173	Hospital Clinico San Carlos	Madrid		Spain	28040
174	Start Madrid-Fundacion Jimenez Diaz	Madrid		Spain	28040
175	Hospital Universitario Doce de Octubre	Madrid		Spain	28041
176	Hospital Universitario La Paz	Madrid		Spain	28046
177	Hospital Universitario Puerta de Hierro Majadahonda	Majadahonda		Spain	28220
178	Hospital General Universitario Morales Meseguer	Murcia		Spain	30008
179	Hospital Universitario Virgen de la Victoria	Málaga		Spain	29010
180	Hospital Regional Universitario de Malaga	Málaga		Spain	29011
181	Complexo Hospitalario Universitario de Ourense	Orense		Spain	32005
182	Hospital Universitari son Espases	Palma De Mallorca		Spain	07120
183	Hospital Universitario Nuestra Señora de Valme	Sevilla		Spain	41014
184	Consorcio Hospital General Universitario de Valencia	Valencia		Spain	46014
185	Hospital Arnau de Vilanova	Valencia		Spain	46015
186	Hospital Universitari I Politecnic La Fe	Valencia		Spain	46026
187	Changhua Christian Hospital	Changhua		Taiwan	50006
188	Kaohsiung Chang Gung Memorial Hospital	Kaohsiung		Taiwan	83301
189	Chung Shan Medical University Hospital	Taichung		Taiwan	40201
190	China Medical University Hospital	Taichung		Taiwan	40447
191	Taichung Veterans General Hospital	Taichung		Taiwan	40705
192	Taipei Veterans General Hospital	Taipei		Taiwan	11217
193	Taipei Tzu Chi Hospital	Taipei		Taiwan	231405
194	Linkou Chang Gung Memorial Hospital	Taoyuan		Taiwan	33305
195	National Taiwan University Hospital Yunlin Branch	Yuanlin		Taiwan	00640
196	Chulabhorn Research Institute	Bangkok		Thailand	10210
197	Siriraj Hospital	Bangkok		Thailand	10700
198	Songklanagarind Hospital (Prince of Songkhla University)	Hat Yai		Thailand	90110
199	Srinagarind Hospital (Khon Kaen University)	Mueang Nonthaburi		Thailand	40002
200	Bangkok Hospital Chiang Mai	Mueang Nonthaburi		Thailand	50000
201	Phramongkutklao Hospital	Ratchathewi		Thailand	10400
202	Rajavithi Hospital	Ratchathewi		Thailand	10400
203	Acibadem Adana Hospital	Adana		Turkey	01130
204	Baskent University Practice and Research Hospital Adana - Medical Oncology Department	Adana		Turkey	01240
205	İInönü Üniversitesi Tip Fakültesi	Battalgazi		Turkey	44280
206	Trakya University Medical Faculty	Edirne		Turkey	22030
207	Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty	Istanbul		Turkey	34096
208	Istanbul Medeniyet Uni Goztepe Training & Res Hosp	Istanbul		Turkey	34854
209	Ege University Medical Faculty	İzmir		Turkey	35100
210	Necmettin Erbakan University Selcuklu Faculty of Medicine	Meram		Turkey	42090
211	Bukovynian Clinical Oncology Center	Chernivtsi		Ukraine	58013
212	Komunalne Nekomertsiine Pidryiemstvo - Miska Klinichna Likarnia #4	Dnepropetrovsk		Ukraine	49102
213	Komunalne Nekomertsiine Pidryiemstvo Oblasnyi Tsentr Onkolohii	Kharkiv		Ukraine	61070
214	Kryvyi RIH Oncological Dispensary	Kryvyi Rih		Ukraine	50048
215	Medical Center "Verum" Limited Liability Company	Kyiv		Ukraine	03039
216	Public Non-profit Institution "Kyiv City Clinical Oncology Center"	Kyiv		Ukraine	03115
217	Volyn Regional Medical Center of Oncology	Luts'k		Ukraine	43018
218	Lviv State Regional Oncology Treatment and Diagnostic Center	Lviv		Ukraine	79031
219	Odessa Regional Oncological Dispensary	Odesa		Ukraine	65010
220	Communal Non-Profit Enterprise of Sumy Regional Council Sumy Regional Clinical Oncological Dispensar	Sumy		Ukraine	40003
221	Zakarpatska Regional Clinical Oncological Center	Uzhgorod		Ukraine	88011
222	Podolsk Regional Oncology Center	Vinnytsia		Ukraine	21029
223	Zaporozhye Regional Antitumor Center	Zaporizhia		Ukraine	69061
224	Medical Center of Llc Oncolife	Zaporizhzhya		Ukraine	69059